SCHEMBL5330843

SCHEMBL5330843

COc1ccc2[nH]c(-c3cccc4c3C(=O)NC4=O)cc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 5/20 0.67
KDR P35968 5/20 0.67
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
PDGFRB P09619 3/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
AXL P30530 1/20 0.46
ITK Q08881 2/20 0.45
ROCK2 O75116 1/20 0.45
CHEK1 O14757 1/20 0.45
WEE1 P30291 1/20 0.45
PDGFRA P16234 2/20 0.45
CDK4 P11802 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5314912 0.81 KDR (1.00) AURKAKDRKDM4EMAPTMEN1
SCHEMBL6820721 0.79 KDM4E (0.59) AURKAKDRKDM4EMAPTMEN1
SCHEMBL9469072 0.74 KDM4E (0.64) AURKAKDRKDM4EMAPTMEN1
SCHEMBL6118322 0.74 RAB9A (0.64) AURKAKDRKDM4EMAPTMEN1
SCHEMBL7066063 0.74 MEN1 (0.59) AURKAKDRKDM4EMAPTMEN1
SCHEMBL15073408 0.73 KDM4E (0.82) AURKAKDRKDM4EMAPTMEN1
SCHEMBL25175575 0.73 KDM4E (0.62) AURKAKDRKDM4EMAPTMEN1
SCHEMBL6303491 0.72 KDM4E (0.61) AURKAKDRKDM4EMAPTMEN1
SCHEMBL903530 0.72 KDM4E (0.60) AURKAKDRKDM4EMAPTMEN1
SCHEMBL3009057 0.72 KDM4E (0.79) AURKAKDRKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US claimed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO claimed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders JANSSEN PHARMACEUTICA, N.V. (BE) 2007-07-12 US disclosed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO disclosed
WO-2007047646-A2 SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161648-A1 Substituted dihydro-isoindolones useful in treating kinase disorders MAP3K20, MAP3K3, MAP3K19 AURKA 669/4885KDR 1627/4885KDM4E 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.